Dr. Kelley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 Medical 530 420 120 Plz
# 365
Los Angeles, CA 90095Phone+1 310-794-9718Fax+1 310-301-8751
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2006 - 2009
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2002 - 2005
David Geffen School of Medicine at UCLAClass of 2002
Certifications & Licensure
CA State Medical License 2003 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma Start of enrollment: 2009 Nov 17
- A Study of LY2157299 in Participants With Hepatocellular Carcinoma Start of enrollment: 2011 Mar 30
- A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Start of enrollment: 2016 May 19
- Join now to see all
Publications & Presentations
PubMed
- 168 citationsBiliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.A Vogel, J Bridgewater, J Edeline, R K Kelley, H J Klümpen
Annals of Oncology. 2023-02-01 - 477 citationsHepatobiliary cancers, Version 2.2021Al B. Benson, Michael I. D’Angelica, Daniel E. Abbott, Daniel A. Anaya, Robert A. Anders
Journal of the National Comprehensive Cancer Network. 2021-05-01 - 33 citationsTemporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017.Milind Javle, Sunyoung Lee, Nilofer S Azad, Mitesh J Borad, Robin Kate Kelley
The Oncologist. 2022-10-01
Lectures
- Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC...2019 ASCO Annual Meeting - 6/1/2019
- Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker ...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Authored Content
- Atezolizumab plus Bevacizumab — A Landmark in Liver CancerMay 2020
Press Mentions
American Association for Cancer Research, April 14-19May 8th, 2023- Fears Rise That UC Strike Could Have Long-Lasting Consequences on Vaunted Research, TeachingNovember 28th, 2022
- Priming Tremelimumab Dose Regimen Shows Promising Benefit-Risk Profile in HCCOctober 19th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
